CALC Insider Filing: Director Eric Roberts Reports Purchase at $3.15 Avg

Rhea-AI Filing Summary

CalciMedica insider purchase and holdings summary. Eric W. Roberts, who is listed as a director, a 10% owner and Chief Business Officer, reported a purchase of 2,343 shares of CalciMedica common stock on 09/09/2025 at a weighted average price of $3.1488 (price range $2.75–$3.21). The filing lists total beneficial ownership following the reported transactions across multiple accounts and entities: 73,250 shares (FMTC Custodian Roth IRA), 179,706 shares disposed, 49,894 shares (Oppenheimer custodian Roth IRA), 10,661 shares (IRA Financial Trust), 356,989 shares (Valence Investments SPV IV, LLC), 66,228 shares (Valence Investments SPV V, LLC), and 316,109 shares (Valence Investments SPV VI, LLC). The filer signed through an attorney-in-fact.

Positive

• Insider purchase reported: 2,343 shares purchased at a weighted average price of $3.1488 on 09/09/2025.
• Substantial existing ownership: Multiple indirect holdings listed (SPVs and custodial IRAs) totaling significant share counts across accounts.
• Transparent pricing disclosure: Filing provides weighted average price and range ($2.75–$3.21) and offers to supply per-price purchase details upon request.

Negative

• None.

Insights

Securities Analyst

TL;DR: A modest insider buy by a significant holder; reinforces existing ownership but is not transformational.

The reported purchase of 2,343 shares at a weighted average price of $3.1488 is a direct purchase by Eric W. Roberts, who is a director, 10% owner and Chief Business Officer. The filing shows large indirect holdings across several custodial and SPV accounts, indicating Roberts maintains substantial exposure to CALC through multiple vehicles. The single small purchase itself is unlikely to materially change ownership percentages, but it is consistent with continued insider participation in the equity. No options, conversions, or derivative transactions are reported in this Form 4.

Corporate Governance Expert

TL;DR: Insider disclosure is complete and shows complex indirect holdings; governance disclosures appear routine.

The Form 4 identifies the reporting person as director, officer and 10% owner and details both direct and multiple indirect holdings through custodial accounts and SPVs. The filing includes the weighted average purchase price and price range, and it is executed via attorney-in-fact. From a governance perspective, the disclosure meets Section 16 reporting requirements by listing transaction code, amounts and ownership form. There are no disclosed departures, derivative exercises, or atypical transactions that would raise immediate governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Eric W

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		P		2,343	A	$3.1488(1)	73,250	I	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock								179,706	D
Common Stock								49,894	I	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
Common Stock								10,661	I	By IRA Financial Trust Company CFBO Eric W. Roberts
Common Stock								356,989	I	By Valence Investments SPV IV, LLC
Common Stock								66,228	I	By Valence Investments SPV V, LLC
Common Stock								316,109	I	By Valence Investments SPV VI, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average purchase price for the transaction reported was $3.1488, and the range of prices were between $2.75 and $3.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

	/s/ John Dunn, Esq., Attorney-in-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Eric W. Roberts report on the Form 4 for CALC?

The Form 4 reports a purchase of 2,343 shares of CalciMedica common stock on 09/09/2025 at a weighted average price of $3.1488.

What roles does the reporting person hold at CalciMedica (CALC)?

The filing lists Eric W. Roberts as a Director, a 10% owner, and the Chief Business Officer.

Does the Form 4 show other holdings or accounts for Eric W. Roberts?

Yes. The filing shows indirect beneficial ownership across several accounts including FMTC Custodian Roth IRA (73,250 shares), Oppenheimer custodian Roth IRA (49,894), IRA Financial Trust (10,661), and Valence Investments SPVs (356,989, 66,228, 316,109 respectively).

Were any derivative securities reported on this Form 4 for CALC?

No derivative securities (options, warrants, or convertible instruments) are reported in Table II of this Form 4.

What price range did the Form 4 disclose for the reported purchase?

The filing discloses a purchase price range of $2.75 to $3.21 and a weighted average price of $3.1488.